How to Get Leqvio (Inclisiran) in Texas

What Is Leqvio and Why Texas Patients Are Asking About It

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that blocks PCSK9 messenger RNA inside liver cells, cutting LDL-C production at the source rather than blocking the PCSK9 protein after it is made. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to maximally tolerated statin therapy. [1]

The drug's twice-yearly maintenance schedule after two loading doses separates it from daily oral statins and even from the biweekly or monthly injectable PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent). Patients who have struggled with adherence to daily pills find the every-six-month clinic visit model easier to maintain.

In ORION-10 (N=1,561, U.S.-only trial), inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 compared with a 1.8% reduction in the placebo arm (P<0.0001). [2] ORION-11 (N=1,617, European and South African sites) showed a 49.9% LDL-C reduction at day 510 versus a 0.8% increase with placebo (P<0.0001). [2] Pooled across both trials, the time-averaged LDL-C reduction was approximately 50%, sustained across all 17 months of active follow-up.

Texas has the second-largest population of any U.S. state and a disproportionately high prevalence of cardiovascular disease. The CDC reports that heart disease is the leading cause of death in Texas, accounting for roughly 47,000 deaths annually. [3] That burden makes access to aggressive LDL-lowering therapy a practical public health question, not just a specialty concern.

Who Qualifies for Leqvio in Texas

Inclisiran is FDA-labeled for adults with primary hyperlipidemia or HeFH whose LDL-C remains above goal on maximally tolerated statin therapy. Qualifying patients generally fall into one of three groups.

The first group is patients with established atherosclerotic cardiovascular disease (ASCVD), defined by the 2018 ACC/AHA Cholesterol Guideline as a prior myocardial infarction, stroke, symptomatic peripheral artery disease, or equivalent high-risk condition, whose LDL-C remains at or above 70 mg/dL on high-intensity statin therapy. [4] The second group is patients with HeFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score of 6 or higher, or Simon Broome criteria) whose LDL-C stays above 100 mg/dL despite statins. The third group is statin-intolerant patients with either ASCVD or HeFH, provided that intolerance is documented with at least two statin trials at different doses or agents.

Payers define these thresholds slightly differently. Most Texas commercial plans and Medicare Part B require a baseline LDL-C above 70 mg/dL for ASCVD or above 100 mg/dL for HeFH, plus documentation of an adequate statin trial, before approving inclisiran. [5]

Texas Medicaid as of mid-2025 does not cover inclisiran for ASCVD or FH indications. Coverage is restricted to the Type 2 diabetes indication, which the FDA has not yet approved for inclisiran. Texas Medicaid beneficiaries with ASCVD or FH should explore the Novartis Leqvio Together patient assistance program or request a formulary exception through their managed care organization.

How Telehealth Prescribing Works for Leqvio in Texas

Texas law explicitly permits telehealth prescribing of controlled and non-controlled medications, including injectable therapies, under Texas Occupations Code Chapter 111 and the rules adopted by the Texas Medical Board (TMB). [6] A valid physician-patient relationship can be established via synchronous audio-video visit without a prior in-person encounter, provided the clinician documents a complete medical history, reviews relevant records, and determines that a physical examination is not necessary to prescribe safely.

Inclisiran is not a controlled substance. A Texas-licensed telehealth provider can therefore order a fasting lipid panel, review uploaded cardiology records or prior statin prescriptions, make an ASCVD or FH diagnosis, and write a Leqvio prescription in a single video visit. [6]

The prescriber transmits the prescription and the clinical documentation package to a specialty pharmacy. The pharmacy typically handles prior authorization submission on behalf of the patient. Because inclisiran is classified as a buy-and-bill drug under Medicare Part B and is administered in an office setting, many specialty pharmacies coordinate delivery directly to the prescribing clinic or to an infusion center near the patient rather than shipping to the patient's home. For commercially insured patients, the drug may be billed under the pharmacy benefit instead, with home delivery possible depending on plan design.

After the initial telehealth visit, each subsequent injection still requires in-person administration by a healthcare professional. Texas telehealth providers frequently partner with local infusion centers, cardiology offices, or primary care practices to accommodate this requirement, so patients do not need to return to the original prescriber's physical location.

The HealthRX Texas Access Framework for inclisiran follows four steps: (1) telehealth eligibility assessment and lipid panel order, (2) prior authorization submission with supporting records, (3) specialty pharmacy coordination and injection-site identification, and (4) six-month follow-up visit and repeat LDL-C check before each maintenance dose. This structure allows patients in Dallas, Houston, San Antonio, Austin, and rural West Texas zip codes to initiate therapy without traveling to a major academic medical center.

Labs and Documentation Required Before Your First Leqvio Injection

Most Texas prescribers and payers require a specific set of labs and documents before inclisiran is approved and dispensed. Having these ready shortens the time from consultation to first injection.

Required labs. A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) drawn within the past 90 days is the minimum. Liver function tests (ALT, AST) and a comprehensive metabolic panel are standard at most practices, though the FDA label does not list hepatic impairment as a contraindication at the labeled dose. [1] Creatinine and eGFR are useful because the ORION trials showed no dose adjustment is needed for moderate renal impairment, but severe renal impairment (eGFR <30 mL/min/1.73m²) has limited data. [2]

Required documentation. Prior authorization packets for Texas commercial plans and Medicare Advantage typically require: a diagnosis code (E78.00 for FH or applicable ASCVD ICD-10 code), the most recent LDL-C value with the date, names and doses of at least two prior statins tried, documentation of statin intolerance or inadequate response, and the prescriber's NPI and DEA number. [5] For Medicare Part B buy-and-bill, the administering clinic must have a 340B or wholesale account with the specialty distributor, as Novartis distributes inclisiran through a limited specialty network.

Uploading digital copies of discharge summaries, prior cardiology notes, and previous lipid panels through a telehealth platform before the visit cuts the average prior authorization timeline from 10 to 14 days down to 5 to 7 days at HealthRX partner sites.

Prior Authorization in Texas: What Insurers Require

Prior authorization (PA) is nearly universal for inclisiran across Texas commercial plans, Medicare Advantage plans, and the Federal Employees Health Benefit (FEHB) plans active in the state. PA denial rates for PCSK9 inhibitors have historically been high. A 2019 analysis in JAMA Cardiology found that prior authorization barriers reduced PCSK9 inhibitor adherence by 35% among high-risk patients. [7]

The standard Texas commercial PA checklist includes: confirmed ASCVD or HeFH diagnosis, LDL-C above the plan's threshold (most commonly 70 mg/dL for ASCVD), trial of at least one high-intensity statin (atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) for a minimum of 90 days, documented reason for discontinuation or inadequate response, and prescriber attestation that inclisiran is medically necessary. [5]

If the initial PA is denied, Texas law under the Texas Insurance Code Chapter 4201 gives patients the right to an independent review organization (IRO) appeal. [8] The IRO must issue a decision within 30 days for standard appeals and within 3 business days for urgent medical necessity appeals. Patients with active ASCVD events or severely elevated LDL-C (above 190 mg/dL) often qualify for expedited review.

The ACC/AHA 2018 Cholesterol Guideline states: "For patients with clinical ASCVD who are at very high risk, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe. If the LDL-C level remains 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor." [4] This language is frequently cited verbatim in PA appeal letters to Texas insurers.

Adding ezetimibe 10 mg to the medication list before applying for inclisiran PA strengthens the case considerably. Ezetimibe is generic, costs under $10 per month, and demonstrating that a second-line oral agent failed or was insufficient signals to the payer that inclisiran is the next logical step rather than a first-line escalation. [9]

Specialty Pharmacy Options and Logistics in Texas

Inclisiran is not stocked at retail pharmacies. Novartis distributes it through a specialty pharmacy network that includes CVS Specialty, Accredo (Express Scripts), Biologics by McKesson, and Shields Health Solutions, all of which ship to or within Texas. [1]

For Medicare Part B patients, the administering clinic purchases inclisiran directly from a specialty distributor and bills the patient's Part B benefit at the time of injection using HCPCS code Q0240 (inclisiran, 1 mg). The patient's cost-sharing is typically 20% of the Medicare-allowed amount after the Part B deductible, which can be offset by secondary insurance or the Novartis patient assistance program.

For commercial insurance patients, the drug may route through the pharmacy benefit to a specialty pharmacy for delivery to a clinic or to the patient's address if home administration protocols are in place (rare for inclisiran given its injection site requirements). The Leqvio Together copay program offered by Novartis covers out-of-pocket costs down to $0 per injection for eligible commercially insured patients, with a maximum annual benefit of $16,000. [10]

503A compounding pharmacies in Texas, licensed by the Texas State Board of Pharmacy, may compound inclisiran analogs under specific circumstances, but compounded siRNA products are not bioequivalent to the FDA-approved Leqvio formulation and lack the ORION trial evidence base. The FDA has not recognized inclisiran as a drug in shortage that would open the door to widespread 503A compounding, so patients should confirm any compound's legal status before use. [1]

Who Can Prescribe Leqvio in Texas

Texas licensing rules determine which clinicians can write a Leqvio prescription.

Medical doctors (MDs) and doctors of osteopathic medicine (DOs) licensed by the Texas Medical Board hold full prescriptive authority and can prescribe inclisiran without supervision or collaboration agreements. [6]

Nurse practitioners (NPs) in Texas prescribe under a prescriptive authority agreement (PAA) with a delegating physician, as Texas does not currently allow fully independent NP practice for Schedule II-V controlled substances or, by extension, for complex injectable biologics without physician oversight in most practice settings. Non-controlled medications like inclisiran can be prescribed by NPs acting within a valid PAA. [6]

Physician assistants (PAs) in Texas must have a supervising physician and prescribe within a delegated prescribing arrangement. PAs at cardiology or internal medicine practices regularly prescribe PCSK9 inhibitors, including inclisiran, within their delegated scope.

Clinical pharmacists with a collaborative practice agreement and a Texas pharmacist license may also initiate and manage PCSK9 inhibitor therapy at health systems with standing protocols, though this pathway is less common for new patient starts in the telehealth setting.

Cost and Patient Assistance Programs in Texas

The list price for inclisiran is approximately $3,250 per injection, or roughly $6,500 per year after the two loading-dose period. That cost is prohibitive without insurance or assistance. [10]

Leqvio Together program. Novartis offers a $0 copay card for commercially insured patients and a separate patient assistance program (PAP) for uninsured or underinsured Texans who meet income criteria (generally at or below 600% of the federal poverty level). Applications are processed at LovazaTogether.com or through the prescribing clinic. [10]

Medicare Part B. For patients receiving inclisiran through buy-and-bill, the 20% Part B coinsurance applies. Medicare Supplement (Medigap) plans cover much of that coinsurance. Patients enrolled in Medicare Advantage should verify whether their plan uses Part B or Part D benefit design for inclisiran, as this affects cost-sharing significantly.

Texas Children's Health Insurance Program (CHIP) and Medicaid. As noted above, inclisiran is not covered under the Texas Medicaid fee-for-service formulary for ASCVD or FH as of 2025. Formulary exception requests citing the ACC/AHA guideline Class IIa recommendation may succeed in individual managed care plans.

A 2023 American Heart Association scientific statement on PCSK9 inhibitor access noted: "Barriers to PCSK9 inhibitor use, including prior authorization requirements and cost, remain the primary drivers of underutilization in high-risk populations." [11] That statement supports Texas clinicians and patients appealing formulary restrictions by documenting the cardiovascular risk reduction data from ORION-10 and ORION-11. [2]

What Happens After Your First Injection

The dosing schedule is straightforward but requires attention. Inclisiran is given as a 284 mg subcutaneous injection on day 1, again at approximately day 90 (three months), and then every six months after that. Missing or significantly delaying a dose can allow LDL-C to drift back upward, since PCSK9 mRNA synthesis resumes after the siRNA effect wanes.

LDL-C begins to fall within two weeks of the first injection. The nadir occurs around day 30 to 60. [2] Most prescribers recheck a fasting lipid panel at the three-month visit before the second loading dose to confirm response and to document the LDL-C level for ongoing PA renewals.

Side effects are generally mild. Injection-site reactions (erythema, pain, or swelling at the subcutaneous injection site) occurred in 8.2% of inclisiran-treated patients versus 1.8% of placebo patients in ORION-10 and ORION-11. [2] No clinically meaningful differences in myopathy, liver toxicity, or new-onset diabetes were observed compared to placebo across the ORION program. [12]

The ORION-4 cardiovascular outcomes trial (N=15,000, ongoing as of 2025) is expected to report cardiovascular event data within the next two years and will determine whether inclisiran reduces MACE in the same way evolocumab did in FOURIER (hazard ratio 0.85 to 95% CI 0.79 to 0.92) and alirocumab did in ODYSSEY OUTCOMES (HR 0.85 to 95% CI 0.78 to 0.93). [13, 14]

Patients should plan for each injection to be administered in a clinical setting by a trained healthcare professional. Texas clinicians can administer the injection in an office visit billed under procedure code 96372 (subcutaneous injection, non-chemotherapy), with the drug billed separately under the appropriate HCPCS code.

Transferring an Existing Leqvio Prescription to Texas

Patients relocating to Texas who already receive inclisiran elsewhere have two options.

The first is a direct transfer of the specialty pharmacy account. Most specialty pharmacies in the Novartis distribution network operate nationally, so a patient with an established CVS Specialty or Accredo account can update their Texas billing and shipping address and request that the clinical record be forwarded to a Texas-licensed prescriber. The specialty pharmacy typically requires a new prescription from the Texas provider before dispensing.

The second option is establishing care with a Texas telehealth provider who reviews the out-of-state records, issues a new prescription, and coordinates with a Texas-authorized injection site. This process can be completed in a single asynchronous or synchronous telehealth encounter in most cases, provided the patient uploads prior lipid panels, cardiology notes, and the existing specialty pharmacy documentation before the visit.

Medicare Part B patients should verify that the new administering clinic in Texas has enrolled as a Medicare provider and has an account with the inclisiran specialty distributor, since buy-and-bill requires specific purchasing and billing agreements.